久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Key vaccine in high demand, but supplies short

By LIU ZHIHUA | China Daily | Updated: 2019-07-05 07:08
Share
Share - WeChat
A woman has a 9-valent vaccine shot in Zhengzhou, capital of Henan province. Each year, some 131,500 new cervical cancer cases are reported in China, and about 53,000 patients die from the disease. ZHANG TAO/FOR CHINA DAILY

Once people can acquire the vaccination on a regular basis, the balance between supply and demand will be gradually restored, he said.

According to a report released earlier this year by Horizon Insights, a consultancy in Shanghai, some 300 million Chinese are in the recommended age group for the 2-valent vaccine, 130 million for the 4-valent, and 90 million for the 9-valent. Every year, 8 million people fall into the recommended age group for each vaccine.

Last year, 300,000 people were vaccinated with the 2-valent type, 1.1 million with the 4-valent, and only 100,000 with the 9-valent, resulting in market values of 500 million yuan, 2.7 billion yuan and 400 million yuan, the report said.

About 833,300 doses of the 2-valent vaccine, 3.41 million of the 4-valent and 1.22 million of the 9-valent were released on the market last year, according to the report.

It estimated that the market value for the 2-, 4-and 9-valent vaccines would reach 1 billion yuan, 7.2 billion yuan and 10 billion in times of peak demand.

There will continue to be a shortage of all three types until next year, as the huge demand that exists now cannot be met in a short period, the report said.

Zhao Heng, founder of consulting company Latitude Health, said the shortage could be resolved through increased production and distribution, but as the three types of vaccine are not on the national compulsory vaccination program, it is difficult for the authorities to order pharmaceutical companies to increase supplies.

However, more than a dozen Chinese pharmaceutical companies are developing HPV vaccines ranging from 2-valent to 14-valent, and some have started phase-3 clinical trials while others have only just received approval for such trials, according to the Horizon Insights report.

|<< Previous 1 2 3 4   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 免费一级欧美大片久久网 | 久草视频首页 | 亚洲精品欧美精品 | 欧美一级毛片免费高清的 | 在线视频久 | 国产人成精品 | 在线国产视频 | 日本xxxb孕交 | 久久欧美精品 | 国产精品高清视亚洲一区二区 | 一 级 黄 色 大片 | 成人黄色免费 | 亚洲最大的视频网站 | 真人毛片 | 久久国产欧美日韩精品 | 国产一级真人毛爱做毛片 | 农村寡妇一级毛片免费看视频 | 自拍偷自拍亚洲精品一区 | 亚洲天天 | 久久精品国产影库免费看 | 国产高清天干天天视频 | 成人欧美日韩高清不卡 | 亚洲gogo人体大胆西西安徽 | 特级欧美午夜aa毛片 | 成人自拍视频在线 | 欧美在线一区二区三区精品 | 在线观看精品国内福利视频 | 亚洲欧美日本国产 | 国产午夜亚洲精品理论片不卡 | 国产成人免费午夜在线观看 | 欧美日韩看看2015永久免费 | 韩国毛片视频 | 黄色毛片国产 | 在线免费看a | 国产精品久久久久久久9999 | 男人的天堂在线免费视频 | 国产特黄一级一片免费 | 中文字幕第9页 | 欧美日韩国产亚洲一区二区三区 | 中国美女乱淫免费看视频 | 九九线精品视频 |